Summary & Overview
CPT 11603: Excision of Malignant Skin Lesion, 2.1–3.0 cm
Headline: CPT 11603: Excision of Malignant Skin Lesion (2.1–3.0 cm) — Surgical Code and Clinical Context
Lead: CPT 11603 designates the surgical excision of a malignant skin lesion on the trunk, arms, or legs when the lesion measures 2.1 to 3.0 cm in diameter. This code defines scope of service and procedural reporting for a common dermatologic and surgical oncology intervention performed across ambulatory settings.
What the code represents and why it matters: CPT 11603 is used to document removal of medium-sized malignant skin lesions with margins, a key step in definitive treatment and staging for cutaneous malignancies. Accurate coding affects clinical records, claim adjudication, and quality measurement for skin cancer care.
Key payers covered: Analysis and guidance address common national payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare.
Overview of what readers will learn: The publication explains the clinical context for using CPT 11603, contrasts it with related lesion-size codes, and summarizes typical site-of-service considerations for office and outpatient facility settings. It outlines common billing practices such as procedural grouping and reporting conventions, notes pertinent coding correlations, and flags areas where documentation should support lesion size and surgical margins. Service-line metadata is not available in the input where indicated.
Intended use: This summary serves clinicians, coding professionals, and policy analysts seeking a concise reference for procedural definition, payer scope, and the clinical circumstances tied to CPT 11603 without making clinical or billing recommendations.
CPT Code Overview
CPT 11603 describes the excision of a malignant skin lesion, including margins, on the trunk, arms, or legs for a lesion with a diameter of 2.1 to 3.0 cm. This is a surgical procedure on the skin intended for removal of malignant lesions and includes the necessary margins for oncologic control.
Service type: Surgical procedure on skin (Excision of malignant skin lesion).
Typical site of service: Most commonly performed in an office or outpatient facility (for example, POS 11 or POS 19).
Clinical & Coding Specifications
Clinical Context
A patient in the outpatient dermatology clinic presents with a biopsy-proven malignant skin lesion on an extremity or trunk. The lesion measures between 2.1 and 3.0 cm in greatest diameter and requires surgical excision with margins. The clinical workflow typically includes preoperative evaluation in the office, informed consent, local anesthesia, complete excision of the lesion with appropriate surgical margins, hemostasis, and wound closure. Postoperative instructions and pathology submission for margin assessment are performed in the same visit or outpatient encounter.
Coding Specifications
-
Modifiers
-
59: Use when the excision represents a distinct procedural service separate from other procedures performed in the same session (for example, separate anatomical sites or unrelated procedures). -
51: Use when multiple procedures are performed during the same encounter to indicate that more than one procedure code is reported. -
Provider Taxonomies
| Taxonomy Code | Specialty |
|---|---|
207N00000X | Dermatology Physician |
207ND0101X | MOHS-Micrographic Surgery Physician |
208600000X | Surgery Physician |
-
Notes
-
Use of the listed modifiers depends on the encounter specifics: separate anatomic sites or distinct services justify
59; concurrent multiple procedures justify51.
Related Diagnoses
-
C43.0— Malignant melanoma of scalp and neckClinical relevance: Melanoma in this anatomic region may require surgical excision with margins; while
11603describes excisions on trunk, arms, or legs, documentation must support the anatomic site and lesion size when using this CPT code. -
C43.11— Malignant melanoma of right ear and external auricular canalClinical relevance: Malignant melanoma of the ear may be surgically excised; coding requires alignment between lesion site, size, and the chosen excision code.
-
D03.0— Melanoma in situ of lipClinical relevance: Melanoma in situ indicates non-invasive disease that may be excised; the procedure code selection depends on lesion size and anatomic location consistent with the CPT description.
Related CPT Codes
| CPT Code | Description |
|---|---|
11600 | Excision, malignant lesion including margins, trunk, arms, or legs; lesion diameter 0.5 cm or less |
11602 | Excision, malignant lesion including margins, trunk, arms, or legs; lesion diameter 1.1 to 2.0 cm |
-
11600and11602are size-based sibling codes to11603used for malignant lesion excisions on trunk, arms, or legs. They represent smaller lesion diameter ranges and are alternatives when lesion size falls into those specified ranges. -
These codes are used in the same clinical workflow when lesion size determines the appropriate code; multiple lesion excisions during the same encounter may lead to reporting multiple size-appropriate codes and application of modifier
51or59as indicated.
National Reimbursement Benchmarks
National mean allowed rates for CPT 11603 show UnitedHealth Group and Cigna at the higher end of the commercial spectrum, with UnitedHealth Group highest at $421.41 and Cigna at $374.52, while Blue Cross Blue Shield and BUCA (aggregate commercial) sit in the mid-range near $284.72 and $299.30 respectively. The Medicare national mean ($285.54) is slightly below the BUCA (average commercial) mean ($299.30), indicating Medicare reimbursement is close to, but modestly lower than, aggregate commercial averages for this code.
Rate dispersion measured as the difference between the 75th and 25th percentiles varies across payers. Cigna and UnitedHealth Group show the widest dispersion (Cigna: $221.50 range; UnitedHealth Group: $255.34 range), indicating broader variability in allowed amounts. Medicare exhibits the tightest dispersion (range $28.00), followed by Aetna (range $112.00) and BUCA (range $154.08), reflecting relatively narrower variability for Medicare and some commercial plans. The table and chart below present the full percentile and mean breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.